Skip to content

Efficacy of Duloxetine Compared to NSIADs in Osteoarthritis of Knee

Efficacy of Duloxetine Compared to NSIADs in Osteoarthritis of Knee: A Randomized Open Labelled Clinical Trial

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05486026
Acronym
Duloxetine
Enrollment
200
Registered
2022-08-03
Start date
2022-08-20
Completion date
2023-01-02
Last updated
2023-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteo Arthritis Knee

Keywords

Duloxetine, Osteoarthritis, Kurdistan Region

Brief summary

Osteoarthritis (OA) is the most common degenerative joint disease, affecting more than 25% of the population . Knee OA is an insidious disease related to structural changes in the joint over many years. Progressive articular damage results in a loss of the extracellular matrix of cartilage in addition to changes in subchondral bone. Duloxetine, a selective serotonin, and norepinephrine reuptake inhibitor, it seems to be effective in treating neuropathic and chronic pain conditions.

Detailed description

This will be a 13-week A randomized open labelled clinical trail in Iraqi Kurdistan Region, that will be designed to assess the efficacy of duloxetine tablet compared with other group (Nonsteroidal anti-inflammatory) drug on the reduction of pain caused by osteoarthritis of the knee. Patients will be divided into two groups, first group (case) will receive duloxetine tablet 30mg for two weeks then titrated up to duloxetine 30mg BID. Patients will be instructed to take the medication with meals. Patients will be observed at visits (0) baseline then at second visits at 13 weeks then will be compared to control group that will receive NSAID (nonsteroidal anti-inflammatory drug) at baseline (0) visit then 2nd visits at 13 weeks.

Interventions

patient in first group (case) will receive duloxetine tablet 30mg for two weeks then titrated up to duloxetine 30mg BID. Patients will be instructed to take the medication with meals. The for 13 weeks

DRUGNonsteroidal Antiinflammatory Drug

patient in this second group will receive NSAID for 3 weeks

Sponsors

Hawler Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Patients will be divided into two groups, first group (case) will receive duloxetine tablet 30mg for two weeks then titrated up to duloxetine 30mg BID. Patients will be instructed to take the medication with meals.

Eligibility

Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

1. \> 40years of age 2. both Genders 3. who will meet the American College of Rheumatology clinical and radiographic criteria for the diagnosis of osteoarthritis of the knee 4. with pain for ≥14days of each separate month for 3months before study entry, with a mean score ≥4 on the 24-h average pain score (0-10) using the average of daily ratings

Exclusion criteria

1. if they have diagnosed with inflammatory arthritis or an autoimmune disease 2. if they received invasive therapy in last 3 months (knee arthroscopy) or knee replacement at any time 3. patients with psychiatric disorders 4. Hypertension 5. Heart disease 6. patients on antipsychotics or anti-depressant -

Design outcomes

Primary

MeasureTime frameDescription
twenty four hour 24-h average pain scores (short form) in patients with osteoarthritis knee painfollow-up patients within two monthsit will report in patients' diaries based on the 11-point Likert scale (an ordinal scale with 0 indicating 'no pain', and 10 indicating 'worst pain imaginable')
(WOMAC) WESTERN ONTARIO AND MCMASTER OSTEOARTHITIS INDEX used for evaluation of pain in knee Osteoarthritisfollow-up patients within two monthswhich involve three category about rating of pain(5 item) , stiffness(2item), physical function(17 item

Secondary

MeasureTime frameDescription
The other modality (clinical global improvement)follow-up patients within two monthswill be used for severity of modality of pain and therapeutic response even side effect of drug

Countries

Iraq

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026